Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy

Yosuke Morodomi, Mitsuhiro Takenoyama, Eiko Inamasu, Ryo Toyozawa, Miyako Kojo, Gouji Toyokawa, Yoshimasa Shiraishi, Tomoyoshi Takenaka, Fumihiko Hirai, Masafumi Yamaguchi, Kenichi Taguchi, Takashi Seto, Kenji Sugio, Yukito Ichinose

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Background: Although patients with the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase gene (EML4-ALK) re-arrangement and epidermal growth factor gene EGFR mutations have proven sensitive to specific inhibitors, there is currently no consensus regarding the sensitivity of non-small cell lung cancer (NSCLC) patients with such mutations to cytotoxic chemotherapy. Patients and Methods: The responses to firstline cytotoxic chemotherapy were retrospectively compared between advanced or postoperative recurrent patients with non-squamous NSCLC who harbor the EML4-ALK fusion gene (ALK+), EGFR mutation ( EGFR+), or neither abnormality (wild-type). Results: Data for 22 ALK+, 30 EGFR+, and 60 wild-type patients were analyzed. The ALK+ group had a significantly lower response rate than the other two groups. Progression-free survival was significantly shorter in the ALK+ cohort compared to the EGFR+ (p<0.001) and wild-type cohorts (p=0.0121). Conclusion: NSCLC patients with the EML4-ALK fusion gene might be relatively insensitivite to cytotoxic chemotherapy.

Original languageEnglish
Pages (from-to)3825-3830
Number of pages6
JournalAnticancer Research
Volume34
Issue number7
Publication statusPublished - Jul 1 2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy'. Together they form a unique fingerprint.

Cite this